Avivomed is developing neuromodulation therapy platforms that target chronic diseases affecting large patient populations through implantable medical devices. The company addresses significant clinical needs by providing effective treatment options for conditions that currently lack adequate solutions.
Funding
Funding not disclosed
Founders
Product
Problem
Many chronic diseases lack effective treatment options, leaving large patient populations with unmet clinical needs. Current therapies may be inadequate or have significant side effects, highlighting the need for innovative solutions.
Solution
Avivomed is developing next-generation neuromodulation therapy platforms using implantable medical devices to address chronic diseases. These platforms aim to provide effective treatment options for conditions where current solutions are lacking. The company focuses on creating innovative therapies to improve patient outcomes and quality of life.
Target Audience
The primary target audience includes patients suffering from chronic diseases and the physicians who treat them.
Features
- Implantable neuromodulation devices for targeted therapy
- Focus on chronic diseases with unmet clinical needs
- Development of novel therapies to improve treatment effectiveness